ABOUT YolTech

YolTech Therapeutics is a pioneering gene editing company dedicated to developing robust gene editing medicines to treat patients with serious diseases. The company has built a leading high-throughput evolution platform and innovative LNP delivery system. YolTech possesses a strong capability for novel Cas and base editor discovery, as well as exceptional in-house LNP production capacity for GMP manufacturing. It holds independent intellectual property rights and core patent protection globally. The company has created a pipeline of 10 genetic medicines focusing on cardiovascular diseases, metabolic diseases, infectious diseases, as well as more common and rare diseases. Clinical trial clearance has been received for its leading asset in March 2024.

50
+

Research Personnel
40
+

Published Papers
10
+

Doctoral Talent

DEVELOPMENT

2024
- Jan
  
  New Members to SAB Appointed
- Feb
  
  Base Editor Patent Granted
- Mar
  
  YOLT-201 IND Application Approved
- Apr
  
  CRISPR/Cas Patent Granted
2023
- Mar
  
  GMP Manufacture Site Established
- Jun
  
  Novel Lipid Patent Granted
- Jun
  
  YOLT-201 GLP Tox Study Completed
  Pre-IND submitted
- Nov
  
  Series A+ Financing
- Dec
  
  IND for leading Asset
  Estimated to have IIT data and IND filing
2022
- Feb
  
  Shanghai R&D Center Established
- Apr
  
  Novel Base Editor Patent Filed
- Jun
  
  Series A Financing
- Jul
  
  Novel CRISPR/Cas Patent Filed
- Aug
  
  Preclinical POC in NHP
  Durable PCSK9 reduction in NHPs after single dose i.v.
2021
- Jul
  
  Company Establishment
- Sep
  
  Angel Round Financing

2024
2023
2022
2021